−0.08USD
−1.18 MUSD
14.36 M
About Merrimack Pharmaceuticals, Inc.
Sector
CEO
Gary L. Crocker
Headquarters
Cambridge
Website
Founded
1993
FIGI
BBG000CQXS37
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
MACK: LongBull Flag consolidation.
- Double top rejected at long term resistance of $9.09
- Fell through $7.31 support
- Bouncing off lower falling channel.
- Multiple falling wedges inside large falling channel.
Target: $11.32
Stop Loss: $5.65
$MACK Merrimack Pharmaceuticals, Golden CrossMerrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company w
$MACK Merrimack Pharmaceuticals Inc Heading HigherShareholders of $MACK are getting a $20 million special dividend.
The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following
MACK - MACK had a huge run forming a fallen angel pattern recently & now seems getting ready for a second phase run.
We would like to see break out of MA100 for long entry, and our first target is 5.93
$MACK Short off previous resistance and 200maEarlier today $MACK spiked towards the 6.50 area (half dollar resistance) and then on the daily it spiked into the 200ma and failed. It has pretty good resistance in that area so i'm looking to see if it will spike up towards the 6.50's area tomorrow and then i'll go short!
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MACK is 14.73 USD — it has increased by 0.07% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Merrimack Pharmaceuticals, Inc. stocks are traded under the ticker MACK.
Merrimack Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
MACK stock is 0.51% volatile and has beta coefficient of 0.19. Check out the list of the most volatile stocks — is Merrimack Pharmaceuticals, Inc. there?
Yes, you can track Merrimack Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
MACK stock has risen by 0.20% compared to the previous week, the month change is a 0.20% fall, over the last year Merrimack Pharmaceuticals, Inc. has showed a 19.76% increase.
MACK net income for the last quarter is −240.00 K USD, while the quarter before that showed −279.00 K USD of net income which accounts for 13.98% change. Track more Merrimack Pharmaceuticals, Inc. financial stats to get the full picture.
Today Merrimack Pharmaceuticals, Inc. has the market capitalization of 214.05 M, it has increased by 0.14% over the last week.
Like other stocks, MACK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merrimack Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Merrimack Pharmaceuticals, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Merrimack Pharmaceuticals, Inc. stock shows the buy signal. See more of Merrimack Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.